
Organization (Industry)
Coloplast (Germany)
ClinicalTrials.gov lists Coloplast (Germany) as lead sponsor of 151 trials. It has 1 approved asset.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 5 registered with a 2026 start date. The hollow diamonds on the dashed line are a forecast of the full-year count, planned starts included: about 6 in 2026 and about 5 in 2027, the average of the 24 months through September, counted as registered and carried forward. The columns, the lighter one included, count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. This method has not been backtested on organizations. In backtests on conditions with as many trial starts a year as this organization (5 to 20), forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.
Logo Coloplast A/S, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers Coloplast (Germany): 151 lead-sponsored trials and 4 legal-entity registrations.
Disease areas (36)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Urinary Incontinence | 21 |
| Pelvic Organ Prolapse | 9 |
| Spinal Cord Injuries | 8 |
| Urinary Incontinence, Stress | 8 |
| Urinary Retention | 8 |
Showing 5 of 36 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 5 |
| 2025 | 6 |
| 2024 | 3 |
| 2023 | 9 |
| 2022 | 10 |
| 2021 | 9 |
| 2020 | 9 |
| 2019 | 4 |
| 2018 | 10 |
| 2017 | 14 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: none of the 151 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (1)
| Drug | Trials |
|---|---|
| Standard Care | 5 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 70% hit target (n=43) | 39% on time (n=44) |
Journals published in (36)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| British journal of nursing (Mark Allen Publishing) | 5 |
| The Journal of urology | 5 |
| Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie | 4 |
| Neurourology and urodynamics | 3 |
| Spinal cord | 3 |
Showing 5 of 36 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 1,023 | 224 | 2025-12-02 |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 4 | 2024-04-17 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| COLOPLAST A/S | HUMLEBAEK Hovedstaden, DK | FDA |
Organization relationships (9)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Iqvia Holdings Inc. | Uses vendor | 2 |
| University of British Columbia | Co sponsors trial with | 1 |
| Pusan National University Yangsan Hospital | Co sponsors trial with | 1 |
| Regional Hospital Central Jutland | Co sponsors trial with | 1 |
| Montecatone Rehabilitation Institute S.p.A. | Co sponsors trial with | 1 |
Showing 5 of 9 relationships.
Latest dated events (1,194)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-08-14 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-02 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-24 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 1,194 events.
Biomarker capability evidence (37)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CIC | Trial collaborator | Named in trial inclusion criteria |
| IPP | Trial sponsor | Named in trial inclusion criteria |
| IPP | Trial sponsor | Named in trial inclusion criteria |
| LARS1 | Trial sponsor | Named in trial inclusion criteria |
| NBN | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 37 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.